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Dear Editor,

I would like to share ideas on the article "Amantadine Treatment for People with COVID-19 ([@bib1])." Araújo R, et al. concluded that "In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19 ([@bib1])." In fact, there are many classic drugs that might be useful for management of COVID-19. Amantadine is an antiviral agent that is in that category. Its exact effect has to be further studied. Although there is a possibility of its advantage, some clinical evidences also imply the non-advantage of this drug. In medicine, amantadine is used for management of Parkisonism. In a simple word, the patients with Parkinsonism who have regular amantadine medication should be free from COVID-19. Nevertheless, the COVID-19 infection among Parkinsonism patients is reported ([@bib2]) and it is questionable o protective effect of amantadine ([@bib3]). Hence, it might imply that amantadine at the dosage for management of Parkinsonism should not effective in management of COVID-19. Further studies are recommended for assessment exact usefulness of amantadine in COVID-19 management.
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